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www.cdatm.orgAbstractObjectives: This article reviews pharmacology, pharmacokinetic properties, clinical efficacy, and safety in metastatic breast
cancer patients, as well as the predictive biomarkers for outcome of treatment with pemetrexed-based regimens.
Methods: PubMed, Embase, OVID, and the Cochrane Library databases were searched from the beginning of each database
without any limitations to the date of publication. Search terms were ‘‘pemetrexed’’ or ‘‘LY231514’’ or “Alimta”, “metastatic
breast cancer”, and “advanced breast cancer”.
Results: There were 15 studies (n ¼ 1002) meeting our criteria for evaluation. Eight single-agent trials (n ¼ 551) and seven using
combinations with other agents (n ¼ 451) were identified that evaluated pemetrexed for use in patients with metastatic breast
cancer. Response rates to pemetrexed as a single agent varied from 8% to 31%, and with combination therapy have been reported to
be between 15.8% and 55.7%. With routine supplementation of patients with folic acid, dexamethasone, and vitamin B12, the
toxicity profile of these patients was mild, including dose-limiting neutropenia and thrombocytopenia, as well as lower grades of
reversible hepatotoxicity and gastrointestinal toxicity. Expression of thymidylate synthase (TS) and other biomarkers are associated
with the prognosis and sensitivity for pemetrexed in breast cancer.
Conclusion: Pemetrexed has shown remarkable activity with acceptable toxicities for treatment of metastatic breast cancer patients.
Translational research on pemetrexed in breast cancer identified biomarkers aswell as additional genes important to its clinical activity
and toxicity. Further research is needed to clarify the role of pemetrexed in breast cancer treatment in order to guide oncologists.
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Fig. 1. Structure of pemetrexed.
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Breast cancer is the most common malignancy among
women and is still a leading cause of mortality in women
worldwide.1 Although impressive improvements have
been made in adjuvant therapy with anthracyclines and
taxanes, development of drug resistance to these agents in
recurrent tumors is common, and a substantial proportion
of breast cancer patients will eventually develop meta-
static disease.2e4 In the management of metastatic breast
cancer, current goals focus on prolonging survival and
maintaining the quality of life by controlling symptoms
and minimizing related toxicity.5 Currently, there is no
single standard to guideoncologists in choosing additional
chemotherapy for patients with metastatic breast cancer
who are refractory to anthracyclines and taxanes.6 Drug
therapy with agents such as capecitabine or ixabepilone is
often used, but the response rates to these therapies are
low.7,8 More efficacious and safe chemotherapeutic
agents, both for monotherapy and in combination with
other agents, are needed to treat this pretreated population
of patients with metastatic breast cancer.
Pemetrexed is a multi-targeted antifolate cytotoxic
chemotherapy agent that has proven activity in several
malignancies, including mesothelioma, lung, breast,
colon, pancreatic, gastric, bladder, head and neck, and
cervical cancers.9,10 Pemetrexed has been approved for
use in combination with cisplatin for first-line treatment
of malignant pleural mesothelioma, as a single agent for
advanced non-small-cell lung cancer (NSCLC), and for
first-line treatment of nonsquamous NSCLC.11 It has a
manageable toxicity profile that includes dose-limiting
neutropenia and thrombocytopenia, as well as lower
grades of reversible hepatotoxicity and gastrointestinal
toxicity. Studies of pemetrexed have shown that the drug
is effective in the treatment of previously treated met-
astatic breast cancer, and has an acceptable toxicity
profile. This paper reviews the pharmacology, pharma-
cokinetics, clinical efficacy, safety, and role in therapy
of pemetrexed in patients with metastatic breast cancer.
Material and methods
Search methods were conducted according to the
Preferred Reporting of Systematic Reviews and Meta-
Analysis (PRISMA) Statement guidelines.12 Medline,
PubMed, Embase, OVID, and the Cochrane Library
were searched from the beginning of each database
without any limitations to the date of publication for
relevant articles on human studies published in En-
glish. Search terms were ‘‘pemetrexed’’ or
‘‘LY231514’’or “Alimta”, “metastatic breast cancer”,and “advanced breast cancer”. The references of
selected articles were also reviewed to identify addi-
tional publications. The study subjects should be pa-
tients with pathologically proven breast cancer who
received pemetrexed containing regimens. Studies that
did not provide at least the objective response rate or
median survival or survival time were excluded.
Results
Therewere 15 studies (n¼ 1002)meeting our criteria
for evaluation. Eight single-agent trials (n ¼ 551) and
seven that used combinations with other agents
(n ¼ 451) were identified that evaluated pemetrexed for
use in patients with metastatic breast cancer who had
been pretreated with anthracycline and taxane.
Pharmacology
The chemical name of pemetrexed is N-[4-[2-
amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d] pyr-
imidin-5-yl]ethyl] benzoyl]-1-glutamic acid disodium
salt (Fig. 1). It is a multitargeted antifolate agent that
interferes with the synthesis of nucleic acids, resulting
in a cytotoxic effect on neoplastic cells. Pemetrexed
inhibits several enzymes in the de novo pathways of
pyrimidine and purine biosynthesis which are required
for the growth and survival of both normal cells and
cancer cells, including thymidylate synthase (TS),
dihydrofolate reductase (DHFR), and glycinamide
ribonucleotide formyl transferase (GARFT).13,14 These
multiple mechanisms of action may explain the greater
potency and broader spectrum of antitumor activity of
pemetrexed in preclinical studies compared with other
antimetabolites such as fluorouracil, methotrexate, or
raltitrexed.13 Pemetrexed can inhibit colony formation
of a variety of chemotherapy-resistant cancer cell lines.
Pharmacokinetic profile
Pemetrexed is administered by an intravenous route
only, and it is rapidly eliminated (half-life of 3.5 h and
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the kidneys, with 70e90% of the administered drug
recoverable in the urine within 24 h. Only a limited
amount of the drug is metabolized by the liver.15
Eighty percent of pemetrexed is bound to plasma
proteins, where it gets rapidly distributed and reaches
peak plasmatic levels within 30 min. Its clearance
correlates with renal function and may be safely used
with vitamin supplementation in patients with a
creatinine clearance of 45 ml/min.16 The pharmaco-
kinetics of a pemetrexed dose does not interfere
significantly with the metabolism of other drugs by
cytochrome P450 isozymes; therefore, it is feasible to
safely administer it in combination with many other
cytotoxic or targeted agents.17
Pemetrexed exhibits a moderate toxicity profile at a
dose of 500 mg/m2 by 10-min infusion once every 21
days with myelosuppression being the dose-limiting
toxicity.18 Folic acid added to the diet in preclinical
studies reduced toxicities while maintaining antitumor
activity. Based on this observation and clinical toxic-
ities, folic acid and vitamin B12 dietary supplementa-
tion has been recently introduced into all ongoing
trials.Table 1
Results of single-agent trials with pemetrexed.
Author (year) No. of
evaluable
patients
Median
age
(years)
Dose
(mg/m2)
Chemotherapy
cycle (range)
O
re
ra
Gomez 200620 76 (61) 46 500, q3w 2.9 (1e3) 1
3
O'Shaughnessy200521 80 (75) 53 500, q3w 3 (1e31) 3
3
2
Miles200122 38 (36) 52 600, q3w 5 (1e9) 1
9
Matin200323 77 (72) 55 600, q3w NR 3
1
Spielmann200124 72 (31) 55 600, q3w NR 1
7
1
Llombart-Cussac200625 79 (78) 56 500, q3w 4 (1e23) 7
3
Robert201128 37 (35) 61.4 600, q2w NR 1
8
Llombart-Cussac200743 47 56 600, q3w 6 (1e29) 8
45 61 900, q3w 5 (1e18) 2
5
CR: complete response; PR: partial response; SD, stable disease; NR: not reClinical efficacy
Single-agent studies with pemetrexed in metastatic
breast cancer
Single-agent pemetrexed has shown promising ac-
tivity and a favorable toxicity profile in patients with
locally advanced or metastatic breast cancer.19 Those
patients were untreated or minimally pretreated with
one or two prior chemotherapies, or heavily pretreated
with three to five prior chemotherapies. Depending on
the degree of the previous cumulative treatment,
response rates ranged from 31% in the cohort of pre-
viously untreated patients20 to 8% in the most heavily
pretreated cohort tested21 (Table 1).
Three recent single-group, phase II clinical trials
have demonstrated single pemetrexed activity and a
manageable safety profile in patients with refractory
metastatic breast cancer. In one study conducted by
Gomez and colleagues,20 61 advanced breast cancer
patients were given pemetrexed (500 mg/m2) on a 21-
day cycle. The objective response rate was 31% (all
partial responses) and the stable disease rate was 56%.
In another study by Miles and colleagues,22 38 patients
with metastatic breast cancer were given pemetrexedbjective
sponse
te (%)
Duration of
response
(months)
Overall
survival
(months)
Toxicities
9 PR (31) NR NR G4 neutropenia (8.2%)
4 SD (56) G3 aminotransferase (52.4%)
CR (4) 5.8 8.2 G3/4 neutropenia (38.8%)
PR (4) G3 lymphopenia (35.0%)
7 SD (36) G3/4 aminotransferase (27.6%)
CR (3) 8 13 G3/4 neutropenia (47.0%)
PR (25) G3/4 thrombocytopenia (15.7%)
G3/4 rash (18.2%)
CR (4) 5.5 NR G3/4 neutropenia (56.0%)
2 PR (16) G3/4 thrombocytopenia (19.0%)
G3/4 rash (10.0%)
CR (3) 5.4 12.8 G3/4 neutropenia (58.0%)
PR (23) G3/4 thrombocytopenia (16.0%)
3 SD (42) G3/4 nausea (10.0%)
PR (9) 3.1 10.5 G3/4 neutropenia (36.4%)
5 SD (45) G3/4 lymphopenia (53.3%)
G3/4 aminotransferase (7.7%)
CR (3) 4.1 18.9 G3/4 neutropenia (37.2%)
PR (23)
PR (17) 4.2 NR G3/4 neutropenia (19.2%)
G3 leukopenia (6.4%)
CR (4.4) 4.1 21.4 G3/4 neutropenia (13.3%)
PR (11.1) G3 leukopenia (8.8%)
G3 thrombocytopenia (4.4%)
ported.
Table 2
Results of combination trials with pemetrexed.
Author (year) No. of
evaluable
patients
Median
age
(years)
Dose (mg/m2) Chemotherapy
cycle (range)
Objective
response
rate (%)
Duration of
response
(months)
Overall
survival
(months)
Toxicities
Dittrich 201230 42 59 PEM-600, d1 5.5 (1e10) 8PR (19.1) NR NR G3/4 neutropenia (21.5%)
CTX-600, d1, q3w 18SD (42.9) G3/4 leukopenia (16.6%)
61 56 PEM-1800, d1 6 (1e10) 20PR (32.8) 6.6 NR G3/4 neutropenia (27.9%)
CTX-600, d1, q3w 26SD (42.6) G3/4 leukopenia (26.2%)
G3 lymphopenia (35.0%)
Garin200831 50 55.5 PEM-600, d1 8 (1e13) 27PR (54) 10.3 NR G3/4 neutropenia (86.0%)
CBP-AUC ¼ 5.0, d1,
q3w
15SD (30) G3 thrombocytopenia (10.0%)
G3 anemia (18.0%)
Amadori201332 65 (64) 52 PEM-600, d1 6.3 17PR (26.6) 7.7 NR G3/4 neutropenia (36.9%)
CBP-AUC ¼ 5.0, d1,
q3w
23SD (35.9) G3/4 thrombocytopenia (24.0%)
66 (61) 51.5 GEM-1200 6.2 2CR (3.3) 7.5 NR G3/4 neutropenia (60.6%)
VB-30, d1, 8, q3w 16PR (26.3)
Deng201333 19 NR PEM-500, d1 2 3PR (15.8) NR 10.3 G3/4 neutropenia (52.7%)
L#-35, d1, q3w 11SD (57.9) G3/4 thrombocytopenia (21.3%)
Ma CX200634 59 51 PEM-500, d8 5 (1e22) 14PR (24) 3.7 10.3 *G3/4 neutropenia (83.0%)
GEM-1250, d1, 8, q3w 9SD (15) febrile neutropenia (14.0%)
G3/4 thrombocytopenia (27.0%)
Pippen201035 21 50.7 PEM-500, d1 4 (1e8) 5PR (23.8) 4.01 16.2 G3/4 neutropenia (71.0%)
GEM-1000, d1, 8, q3w 10SD (47.6) febrile neutropenia (10.0%)
G3/4 leukopenia (24.0%)
52 53.5 PEM-500, d1 5 (1e38) 2CR (3.85) 3.19 13.4 G3/4 neutropenia (33.0%)
GEM-1500, d1, 8, q2w 8PR (15.38) febrile neutropenia (6.0%)
26SD (50) G3/4 leukopenia (14.0%)
Dent201036 16 (14) 54 PEM-500, d1 5 (1e13) 7SD (50) 3.2 5.9 G3/4 febrile neutropenia (19.0%)
GEM-1500, d1, q2w
PEM: pemetrexed; CTX: cyclophosphamide; CBP: carboplatin; AUC: area under the concentration/time curve; L#: Lobaplatin; GEM: gemcitabine;
VB: vinorelbine; OS: overall survival; CR: complete response; PR: partial response; SD: stable disease; NR: not reported; G: grade; *: without
vitamin B12 and folic acid supplementation.
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response rate was 28%, and median duration of the
response was eight months and the median overall
survival was 13 months. Martin and colleagues23 have
shown similar results with an objective response rate of
20.9%, a stable disease rate was 43%, and the median
duration of response and overall survival were 5.5 and
10.7 months in 72 patients.
Spielmann and colleagues24 investigated using
pemetrexed (600 mg/m2) in 72 metastatic breast
cancer patients who had been heavily pretreated. The
overall response rate was 26%; the median duration
of the response was 5.4 months and median survival
time was 12.8 months. Their study suggests prom-
ising therapeutic activity in metastatic breast cancer
patients previously treated with both anthracyclines
and taxanes. O'Shaughnessy and colleagues21 showed
the same activity of pemetrexed in 80 heavily pre-
treated patients, and improvements in patient-
reported symptoms ranged from 16.2% for theintensity of pain to 32.1% for nausea. Contrarily,
Llombart-Cussac and colleagues25 reported that the
response to pemetrexed salvage treatment was low in
this kind of patient, but was generally well tolerated
by patients who had been previously treated for breast
cancer.
Pemetrexed pharmacokinetic studies in NSCLC
patients have suggested that TS inhibition is short-
lived, especially with concurrent vitamin B12 and
folic acid supplementation, suggesting that an every 2-
week schedule may be optimal.26,27 Therefore, some
studies evaluate the activity of pemetrexed on a
biweekly schedule, as first-line treatment for advanced
or metastatic breast cancer. Robert et al28 used
pemetrexed 600 mg/m2 every 2 weeks as first-line
chemotherapy in 35 evaluable patients, the overall
response rate was 26%, and the clinical benefit rate
was 40%. Median progression-free survival and
overall survival were 4.1 months and 18.9 months,
respectively.
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breast cancer
In various pemetrexed-based combination therapies
for breast cancer, response rates were 15.8e55.7%
when used with cyclophosphamide, carboplatin, or
gemcitabine (Table 2).
Pemetrexed-cyclophosphamide
One study investigated the maximum tolerated
dose (MTD) of pemetrexed and cyclophosphamide
combination therapy for 57 patients with locally
advanced or metastatic breast cancer.29 The dose
escalation started with pemetrexed 400 mg/m2 and
cyclophosphamide 400 mg/m2, and reached tumor
growth delay after 13 dose escalation steps of either
pemetrexed or cyclophosphamide with doses of
2400 mg/m2 of pemetrexed and 600 mg/m2 of
cyclophosphamide. Among the 50 patients evaluable
for efficacy, 13 (26%) patients had a partial response
and 17 (34%) patients had stable disease from the
lowest dose level. They also observed the antitumor
activity measured by the response rate of two
different doses of pemetrexed (600 or 1800 mg/m2) in
combination with cyclophosphamide (600 mg/m2)30;
the group receiving 600 mg/m2 was discontinued as
the response rate (19.1%) was lower than targeted. In
the 1800 mg/m2 arm, the partial response and stable
disease rates were 32.8% and 42.6%, respectively,
and the median progression-free survival was 6.3
months. The initial schedule selected for further
investigation in phase II trials was pemetrexed at
600 mg/m2. During the subsequent phase II devel-
opment the dose of pemetrexed was adjusted to
500 mg/m2 due to bone marrow and gastrointestinal
toxicities. The adjusted dose of pemetrexed was well
tolerated throughout the late-phase drug development
program.
Pemetrexed-platinum-based compounds
A phase II study by Garin and colleagues investi-
gating pemetrexed (600 mg/m2) combined with car-
boplatin (area under the curve of 5) administered every
three weeks in 50 patients with locally advanced (30%)
or metastatic (70%) breast cancer.31 Only one fourth of
the patients had received prior adjuvant chemotherapy.
The partial response rate was 54.0% and the median
time to disease progression was 10.3 months.
A randomized phase II non-comparative study by
Amadori et al32 investigated pemetrexed-carboplatin
and gemcitabineevinorelbine combination therapies
in patients pretreated with anthracycline and taxanes.
Both combinations showed moderate efficacy and werewell tolerated. Deng and colleagues33 observed that the
combination of pemetrexed (500 mg/m2) and lobapla-
tin (35 mg/m2) was modestly active in 19 heavily
pretreated metastatic breast cancer patients. The
response rate was 15.8% and the median survival time
was 10.3 months.
Pemetrexed-gemcitabine
A phase II study34 defined the efficacy and toxicity
of pemetrexed, 500 mg/m2 (intravenous; day 8), in
combination with gemcitabine, 1250 mg/m2 (intrave-
nous; day 1 and 8), in 59 patients with metastatic breast
cancer. The overall response rate was 24%, median
survival time was 10.3months, and the 1-year survival
rate was 49%.
Another phase II trial35 evaluated pemetrexed
500 mg/m2 and gemcitabine 1000 mg/m2 or 1500 mg/
m2 given on a 21-day or a 14-day schedule in patients
with advanced breast cancer previously treated with
taxanes. The response rates were 23.8% and 19.2% and
the median survival times were 16.2 months and 13.4
months, respectively.
In addition, Dent et al36 reported an open label
phase II study of biweekly treatments with the same
combination in patients with metastatic breast cancer.
Sixteen patients received pemetrexed (500 mg/m2) on
day-1 of chemotherapy treatment immediately prior
to gemcitabine (1500 mg/m2). Median progression-
free survival was 3.2 months and median overall
survival was 5.9 months. But this study did not meet
the criteria for proceeding to the second stage of
accrual as the rate of early disease progression was
more than 40% and the response rate was 0. The
different levels of activity may be a reflection of
different baseline characteristics of patients or the
schedule of administration; if gemcitabine had been
preceded by pemetrexed the treatment may have been
more active.
Tolerability
Adverse events of pemetrexed treatment include
dose-limiting myelosuppression, skin rash, mucosal
toxicities, elevation in transaminases and asthenia, as
well as lower grades of reversible hepatotoxicity and
gastrointestinal toxicity. However, since routine sup-
plementation with folic acid, dexamethasone, and
vitamin B12 in patients treated with pemetrexed has
been instituted, the toxicities are modest. In the above
studies clinicians found that the toxicities were
generally less frequent in those who received the
supplementation (Tables 1 and 2). Therefore, this agent
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setting and could be utilized in high risk patients,
especially the elderly or poor performance status
patients.18,37e39 Moreover, pemetrexed with folic acid,
dexamethasone and vitamin B12 can reduce the level of
plasma homocysteine, and thus pemetrexed-associated
toxicities, allowing dose escalation of pemetrexed
without compromising its antitumor activity.40,41
A phase I study42 evaluated the effect of folate or
vitamin supplementation on the toxicity, tolerability,
and pharmacokinetics of pemetrexed in patients with
locally advanced or metastatic breast cancer. In this
study, the pemetrexed doses tolerated with vitamin
supplementation were significantly higher than those
tolerated in earlier studies without supplementation,
and toxicities were independent of the type of vitamin
supplementation or prior myelosuppressive treatment.
The recommended dose of pemetrexed is 1050 mg/m2
in lightly pretreated patients and 800 mg/m2 in heavily
pretreated patients, irrespective of the type of vitamin
supplementation. Therefore, the maximum tolerated
dose of pemetrexed as a single agent is probably higher
than the dose actually utilized in clinical practice.
Llombart-Cussac et al43 observed response rates of
17% and 15.6% when pemetrexed was given at 600
and 900 mg/m2 to metastatic breast cancer patients in a
first-line setting on day-1 of a 21-day cycle. They
showed that lower doses of pemetrexed appear to have
the same activity as when the higher, 900 mg/m2 dose,
was given. The dose of 600 mg/m2 has been the rec-
ommended as the pemetrexed dose for phase II
studies44 and has shown activity in previous phase II
studies in patients with metastatic breast cancer.22e24
Predictive biomarkers for pemetrexed
Recent studies have reported that thymidylate syn-
thase (TS) expression in tumor tissues is significantly
associated with the prognosis in patients with several
types of malignant tumors; such as mesothelioma,
gastric cancer, and colorectal cancer45e49. A clinical
study evaluating 5-FU based therapy in patients with
breast cancer indicated that lower pretreatment levels
of TS protein were predictive of the response to
chemotherapy.50 Gomez and colleagues20 also
explored potential correlations between treatment
outcome (antitumor activity) and molecular target
expression in patients with untreated breast cancer.
Patients with “low” baseline TS expression levels
(71) were more likely to respond to pemetrexed than
patients with “high’’ baseline TS (>71). Hence, lower
pretreatment TS expression levels may be associatedwith enhanced clinical activity of pemetrexed. In
addition, the observed decreases in DHFR and GARFT
expression after pemetrexed treatment highlight the
potential clinical importance of these targets.
Other molecules involved with folate metabolism,
transport, and mechanism of action may similarly
affect pemetrexed efficacy and toxicity. Llombart-
Cussac et al43 assessed 49 patients for the expression
levels of 12 pemetrexed-related genes. They found the
response rates and median time to tumor progression
for high versus low thymidine phosphorylase (TP)
expression were 27.6% versus 6.3% and 5.4 months
versus 1.9 months, and the folylpolyglutamate syn-
thetase (FPGS) high-expression subgroup had greater
response rate and median time to progression than low-
expression subgroup which were 37.5% vs. 10.0% and
8.6 vs. 3.0 months. Only g-Glutamyl hydrolase (GGH)
expression correlated with the occurrence of grade 3/4
toxicities; 78.6% patients with high GGH expression
experienced a grade 3/4 toxicity, whereas for low GGH
expression was 27.3%.
Pippen and colleagues35 found a trend toward an
increased response rate in estrogen receptor-negative
(ERe) patients compared with estrogen receptor-
positive (ERþ) patients on the 14-day pemetrexed
treatment schedule, consistent with previous studies.51
In their study, two patients with ERe/PRe/human
epidermal growth factor receptor 2-negative (HER2e)
tumors achieved CR when treated with the 14-day
schedule. In addition, only 75e80% of human
epidermal growth factor receptor 2-positive (HER2þ)
patients on 14-day and 21-day schedule had previously
received trastuzumab, and a higher rate of trastuzumab
use among the HER2þ patients might have resulted in
higher response rates and/or more durable responses in
that subset of patients. However, it is noteworthy that
HER2þ patients in Pippen's study responded to treat-
ment at a rate comparable to that of the HER2e pa-
tients. Schneeweiss et al52 reported to the contrary that
the clinical effect of pemetrexed-based chemotherapy
in early breast cancer was irrelevant to the hormone
receptor status.
Discussion
The studies discussed in this review demonstrate
that pemetrexed is well tolerated as a single agent and
can be an important contribution to combination
chemotherapy regimens. Pemetrexed can provide an
adequate regimen for metastatic breast cancer therapy.
Dose-dense, single-agent pemetrexed did not appear to
improve efficacy compared to the standard every 3-
33L.-Y. Zhou et al. / Chronic Diseases and Translational Medicine 1 (2015) 27e35week schedule, but its reduced side-effect profile may
make it a fitting agent for use in combination with
other chemotherapeutics or with targeted agents. The
combination of pemetrexed with cyclophosphamide or
platinum-based compounds represents a regimen of
reasonable efficacy and acceptable tolerability for
metastatic breast cancer patients who have been pre-
treated with an anthracycline plus a taxane. Peme-
trexed and gemcitabine is clinically active and a 14-
day schedule appears to result in fewer serious toxic-
ities. Further assessment of this combination in a ran-
domized trial of various breast cancer patient
populations is warranted.
However, it is difficult to compare results of
different studies because of the relatively small number
of patients and potential differences in the patient
populations. Conducting future studies comparing the
combination of pemetrexed and other chemothera-
peutic agents with pemetrexed alone in a larger patient
population would seem to be a reasonable approach.
Therefore, decision-making regarding treatment se-
lection must take into account multiple patient and
tumor factors and the therapeutic indices of the avail-
able treatments should be considered in the context of
the individual patient.
With routine supplementation of patients with folic
acid, dexamethasone, and vitamin B12, the toxicity
profile of these patients was mild, including dose-
limiting neutropenia and thrombocytopenia, as well
as lower grades of reversible hepatotoxicity and
gastrointestinal toxicity. Furthermore, the relative role
of folic acid compared to vitamin B12 should be
scrutinized, whether there is an effect of these vita-
mins on the antitumor effect, and whether vitamin
supplementation may allow for a clinically mean-
ingful dose escalation beyond 600 mg/m2. There is a
clear need for an optimal dose of pemetrexed for
metastatic breast cancer that prolongs survival and is
well tolerated.
Expression of thymidylate synthase (TS) and other
biomarkers are associated with the prognosis and
sensitivity for pemetrexed in breast cancer. The impact
of pemetrexed on the expression of its main target
enzymes needs to be further explored in order to better
predict treatment outcomes and side effects to this
agent. Future translational research studies will include
investigation of biomarkers of pemetrexed treatment as
well as additional genes critical to the folate pathway
and breast cancer. Such studies may ultimately allow
us to create individualized treatment regimens that
offer an improved therapeutic profile by identifying
patients most likely to benefit from pemetrexed. Inaddition, further research is needed to understand the
economic implications of these regimens, including the
broader societal effects and the value to the patients.
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